Lu Dai

Federal Grant PI High Impact

Researcher

University of Arkansas for Medical Sciences

faculty

34 h-index 301 pubs 3,404 cited

Research Areas

Herpesvirus Infections and Treatments Viral-associated cancers and disorders Cancer Treatment and Pharmacology Immune Response and Inflammation SARS-CoV-2 and COVID-19 Research Nanoparticles: synthesis and applications Diet and metabolism studies Behavioral and Psychological Studies

Links

ORCID Lab Website Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Lu Dai's research program investigates the role of specific molecular pathways and viral interactions in the development of cancer and other diseases. A significant portion of his federally funded work focuses on targeting IL1RAP, oncogenic viral proteins via O’PROTACs, and the role of Macrophage Migration Inhibitory Factor (MIF) in virus-associated malignancies. These projects have received substantial funding from the National Institutes of Health (NIH), totaling $687,500 across three awards.

His recent publications reflect a broad range of interests, including the molecular mechanisms of herpesvirus reactivation triggered by SARS-CoV-2 and antiviral drugs, the development of novel materials for food packaging, and the association between metabolic health indicators and depression. Dai's scholarly output is substantial, with an h-index of 34, over 300 publications, and more than 3,400 citations, indicating a highly cited researcher. He actively collaborates with colleagues at the University of Arkansas for Medical Sciences, including Steven R. Post, Shengyu Mu, Lindsey Barrett, and Samantha Kendrick, with whom he has co-authored multiple publications.

Metrics

h-index: 34
Publications: 301
Citations: 3,404

Selected Publications

Developing new ceramide analogs against non-small cell lung cancer (NSCLC) (2024) DOI
Human endogenous retrovirus type K encoded Np9 oncoprotein induces DNA damage response (2024) DOI
Development of human endogenous retrovirus type K‐ related treatments for human diseases (2024) DOI
Role of lymphatic endothelium specific hyaluronan receptor 1 in virus infection and associated diseases (2024) DOI
Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications (2024) DOI
Echinomycin as a promising therapeutic agent against KSHV-related malignancies (2023) DOI
Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas (2023) DOI
Activation of IL1 signaling molecules by Kaposi’s sarcoma-associated herpesvirus (2022) DOI
SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era? (2022) DOI
Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients (2022) DOI
Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target (2022) DOI
The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways (2022) DOI
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus (2021) DOI
Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression (2021) DOI
Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles (2021) DOI